(Q37971360)

26 August 2017

title

Recent advances in management of gout (English)

1 reference

26 August 2017

E Suresh

1

1 reference

26 August 2017

P Das

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

23 December 2011

1 reference

QJM: An International Journal of Medicine

26 August 2017

published in

1 reference

26 August 2017

volume

105

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

407-417

1 reference

Gout epidemiology: results from the UK General Practice Research Database, 1990-1999.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Gout and the risk of acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

The changing epidemiology of gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

The challenges of gout management in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

How interleukin-1β induces gouty arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

A pilot study of IL-1 inhibition by anakinra in acute gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Gouty arthritis in acute cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

21 January 2018

Colchicine in acute gout

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Does colchicine work? The results of the first controlled study in acute gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Systemic steroid therapy for acute gout: a clinical trial and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Response to application of ice may help differentiate between gouty arthritis and other inflammatory arthritides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Diagnosis and management of gout: a rational approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Treating to target: a strategy to cure gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Acute adverse reactions attributed to allopurinol in hospitalised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Fulminant hepatic failure associated with benzbromarone treatment: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Gout therapeutics: new drugs for an old disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Update on gout: new therapeutic strategies and options

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Febuxostat: a new treatment for hyperuricaemia in gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Febuxostat for treatment of chronic gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Advances in gout: some answers, more questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Uricase and other novel agents for the management of patients with treatment-failure gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

PEG-uricase in the management of treatment-resistant gout and hyperuricemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

New advances in the treatment of gout: review of pegloticase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Vitamin C intake and the risk of gout in men: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Recent developments in diet and gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Dietary factors and hyperuricaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Purine-rich foods, dairy and protein intake, and the risk of gout in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Alcohol intake and risk of incident gout in men: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

The influence of dairy products on plasma uric acid in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Four generations of transition-state analogues for human purine nucleoside phosphorylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Imaging of gout: findings and utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

High-resolution ultrasonography of the first metatarsal phalangeal joint in gout: a controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Dual energy computed tomography in tophaceous gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Quality of life and quality of care for patients with gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Gout management: let's get it right this time

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Adherence with urate-lowering therapies for the treatment of gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Development and evaluation of a survey of gout patients concerning their knowledge about gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Uric acid as a CNS antioxidant

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Urate as a predictor of the rate of clinical decline in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Hyperuricemia and incidence of hypertension among men without metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Hyperuricaemia--where nephrology meets rheumatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR242

21 January 2018

Identifiers

DOI

10.1093/QJMED/HCR242

1 reference

26 August 2017

1 reference